Two or more different epidermal growth factor receptor (EGFR) mutations can be detected within a single tumor sample, which represents complex mutations. However, the frequency and efficacy of tyrosine kinase inhibitor (TKI) treatments for patients harboring these mutations are unknown. METHODS: From January 2011 to January 2017, patients diagnosed with EGFR mutations were screened. The effectiveness of TKIs in patients with complex mutations was retrospectively analyzed. RESULTS: A total of 16,840 subjects were screened, and there were 5898 positive patients. One hundred eighty-seven patients (3.2% of all patients with EGFR mutations) had complex EGFR mutations, and 51 of the patients with advanced adenocarcinoma were treated with TKIs as a first-line treatment. The objective response rates for patients who had Del-19121L858R mutations (n 5 15), Del-19/ 21L858R1atypical mutations (n 5 16), double atypical mutations (n 5 8), and complex mutations with a primary drug-resistant pattern (n 5 12) were 75.0%, 60.0%, 71.0%, and 8.3%, respectively. The median progression-free survival times for the 4 groups were 18.2 months (95% confidence interval [CI], 10.6-25.9 months), 9.7 months (95% CI, 3.3-15.8 months), 9.6 months (95% CI, 3.3-19.0 months), and 1.4 months (95% CI, 0.4-2.3 months), respectively. CONCLUSIONS: These results from the largest sample size suggest that EGFR-TKI therapy is effective in patients with Del-19121L858R mutations, Del-19/21L858R1atypical mutations, and double atypical mutations but is less effective in patients with a primary drug-resistant pattern. Patients with the Del-19121L858R mutations may, therefore, benefit more from treatment with first-generation TKIs. Cancer 2018;124:2399-406. V C 2018 American Cancer Society.
INTRODUCTION
Lung cancer is the leading cause of cancer-related deaths both in China and worldwide. 1, 2 Almost 80% of these patients have distant metastases when they are diagnosed, so they are not candidates for curative surgery. 3 Epidermal growth factor receptor (EGFR) can be detected in 10% to 15% of white patients and in 40% to 50% of Asian patients. 4, 5 Several prospective and phase 3 clinical trials have reported that patients with a sensitive EGFR mutation have an objective response rate (ORR) of 70% to 80% with a median progression-free survival (PFS) of approximately 10 months. [6] [7] [8] [9] The in-frame deletion in exon and the point mutation in exon 21 (21L858R) are regarded as the best predictors, and they account for 85% to 90% of all EGFR mutations. 10, 11 It is estimated that 95.3% of patients with advanced lung adenocarcinoma with sensitizing EGFR mutations receive matched therapy, with a clinical benefit documented in 84.8%. 12 Occasionally, 2 or more different EGFR mutations can be found within a single tumor sample, which represents complex EGFR mutations. 13 Theoretically, the molecular conformation change of the EGFR tyrosine kinase domain induced by the introduction of another mutation may lead to increased or decreased affinity for tyrosine kinase inhibitors (TKIs), which will subsequently affect the clinical outcomes.
14 Several previous studies have been reported, but their numbers have been small, and their results have sometimes been conflicting. 12, 15, 16 In addition, a previous study suggested that the likelihood of receiving matched therapy correlated strongly with the predicted drug response to the identified mutation. 12 Thus, conflicting knowledge in this field may lead to the loss of patients who could have potentially benefited from TKI treatment, so additional knowledge about this field is needed. In this study, we summarized clinical data for patients with complex EGFR mutations and investigated the therapeutic efficacy of TKIs in these patients.
MATERIALS AND METHODS

Patients
Our study included patients with pathologically or cytologically confirmed advanced lung adenocarcinoma who were diagnosed at Shanghai Chest Hospital between January 2011 and January 2017. All patients with EGFR mutations were identified from our registration system. Patients were excluded from this study for any of the following reasons: 1) they had the wild type or a single EGFR mutation, 2) they had complex mutations with weak positivity, 3) TKIs were taken as adjuvant treatment or were concurrently combined with chemotherapy or radiotherapy, 4) EGFR complex mutations were confirmed as a result of TKI induction, 5) complete medical records were lacking, and 6) TKIs were not initiated as the first-line treatment. Eligible patients were divided into 4 groups: group A (Del-19121L858R; n 5 15), group B (Del-19/21L858R1atypical mutations; n 5 16), group C (double atypical mutations; n 5 8), and group D (complex mutations with a primary drug-resistant pattern; n 5 12). Specimens used for EGFR mutation detection were obtained by surgery, by fine-needle small biopsy guided by ultrasound or computed tomography, by transbronchial biopsy, or from malignant effusion cell blocks. All the analyses were performed before TKI treatment. Therapeutic and prognostic information was retrospectively collected. The clinical or pathological stage was determined on the basis of the seventh edition of the TNM classification for non-small cell lung cancer. 17 Our study was approved by the institutional review board of Shanghai Chest Hospital, and all the patients provided written consent before invasive procedures and TKI treatment.
EGFR Mutation Detection
Two detection methods, directing sequencing and the amplification refractory mutation system (ARMS), were used. Between January 2011 and May 2012, the direct sequencing method was used as a routine molecular technique. In brief, tumor DNA was extracted from various tumor specimens, quantified, and further amplified by polymerase chain reaction (PCR) with primers for EGFR exons 18 to 21. The PCR products were analyzed by direct standard sequencing after purification. Between May 2012 and January 2017, another cost-effective and time-saving detection method termed ARMS was used for EGFR analyses. In brief, the DNA template, deionized water, and other reaction components were mixed in a reaction system. PCR was performed under specified conditions, and the results were analyzed according to the manufacturer's instructions. More details of the 2 detection methods can be found in previous reports. 18, 19 Treatment and Clinical Assessment
The first-generation TKIs were given orally during the study period. Chest computed tomography scans were performed to assess treatment responses, which were defined as a complete response (CR), a partial response (PR), stable disease (SD), or progressive disease according to the Response Evaluation Criteria in Solid Tumors (version 1.1). The PFS was calculated from the initiation of TKI treatment to disease progression or the last follow-up date (May 31, 2017).
Statistical Analysis
Abnormally distributed continuous variables are expressed as medians and ranges and are further compared with the rank-sum test. Categorical variables are expressed as means of absolute numbers and percentages. The association between complex mutation types and their responses to TKIs were analyzed with Fisher's exact test. Survival curves were generated with the Kaplan-Meier method and were further compared with the log-rank test. A P value < .05 (1-sided) was considered statistically significant. All analyses were performed with the Statistical Package for Social Sciences (version 24.0 for Windows; SPSS, Chicago, Illinois).
RESULTS
Frequency of Complex EGFR Mutations
During the study period, a total of 16,840 patients were screened with 5898 positive patients. The following patients were excluded from this study: patients with a mutation in the exon 19 deletion (n 5 2633), patients with a 21L858R point mutation (n 5 2637), patients with a single atypical mutation in exons 18 to 21 (n 5 311), patients with acquired complex mutations (eg, acquired 20T790M1Del-19/21L858R mutations; n 5 111), and patients with weak positivity (n 5 19). Primary complex EGFR mutations were detected in 187 of 5898 patients with EGFR mutations, and they accounted for 3.2% of the entire EGFR mutation spectrum. The patient selection steps and the mutation types for the 5898 positive patients are shown in Figures 1 and 2A , respectively.
Mutation Location/Type for 187 Patients With Complex Mutations
The concomitant occurrence of exons 20 and 21 was detected in 58 patients, and this was followed by exon 19 and exon 21 synchronous mutations in 45 cases. With respect to the mutation types, 20T790M121L858R
Original Article occurred at the highest frequency (n 5 44), which was slightly higher than the frequency of patients with Del-19121L858R (n 5 42). The frequencies and percentages of the complex EGFR mutations in the 187 patients are shown in Figure 2B ,C.
Clinicopathological Data of the 187 Patients With Compound EGFR Mutations
The baseline clinicopathological characteristics of the 187 patients with compound EGFR mutations are listed in Table 1 . The median age of all the patients was 61 years (range, 34-78 years). There were higher percentages of females (56.7% vs 43.3%) and nonsmokers (75.4% vs 24.6%). Baseline clinicopathological characteristics were well balanced between those who were included in survival analyses (n 5 51) and those who were excluded (n 5 136) except that the former group was significantly older (63 vs 61 years; P 5 .02; Table 1 ).
Responses to TKIs in Previously Untreated Patients With Complex Mutations
Among the 51 patients with advanced lung adenocarcinoma who received TKIs as a first-line treatment, 46 had enough data for their best response during treatment to be evaluated. Among these patients, 4 patients had a CR, 20 showed a PR, 9 had SD, and the remaining 13 were evaluated as having progressive disease. The ORR (CR 1 PR) was 52.2% (95% confidence interval [CI], 37.2%-67.2%), and the disease control rate (CR 1 PR 1 SD) was 71.7% (95% CI, 58.2%-85.3%).
The ORR varied according to the type of mutation. There were 12, 15, 7, and 12 individuals who had enough data to allow a response assessment for group A (Del-19121L858R), group B (Del-19/21L858R1atypical mutations), group C (double atypical mutations), and group D (complex mutations with a primary drug-resistant pattern), respectively, and the ORRs were 75%, 60%, 71%, and 8.3%, respectively. The ORRs in the first 3 groups were similar (group A vs group B, P 5 .41; group A vs group C, P 5 .87; group B vs group C, P 5 .60), and they were significantly higher than the ORR of the fourth group (P < .01). The responses to TKIs in the 4 groups are listed in Table 2 .
PFS of TKI-Treated Patients With Complex EGFR Mutations
The median PFS of the study cohort was 9.5 months (95% CI, 5.4-13.7 months). Patients in group A had the longest PFS (18.2 months; 95% CI, 10.6-25.9 months) in comparison with patients in group B (9.7 months; 95% CI, 3.3-15.8 months; P 5 .13), group C (9.6 months; 95% CI, 3.3-19.0 months; P 5 .46), and group D (1.4 months; 95% CI, 0.4-2.3 months; P < .01). No difference in the PFS was found between group B and group C (P 5 .63; Fig. 3 ). More detailed information about patients in groups B and C is listed in Table 3 . To further assess the clinical outcomes of patients with double classic mutations after TKI treatment, we performed a literature review until 2017 and found 22 TKI-treated patients with concurrent Del-19 and 21L858R mutations. The ORR and PFS were 80.0% and 13.9 months, respectively (Table 4) . [20] [21] [22] [23] [24] [25] [26] The overall survival was too short so far to analyze.
DISCUSSION
The frequencies of complex mutations, ranging from 0.12% to 16%, have been reported in previous studies. 20, [27] [28] [29] [30] Differences in detection methods and ethnicities (Asian or white) may have been responsible for the controversial results. ARMS is the most widely used method in China, but it covers only 29 hotspot mutations and cannot detect unknown mutations. 31 In addition, experimental artifacts due to deamination generated during PCR are also a potential interference factor. 32 The prevalence of complex mutations in our study was 3.2%, which was similar to the prevalence in previous reports. 12, 33 Previous studies have suggested that complex mutations are usually presented as a combination of a classic mutation and an atypical mutation (eg, 18G719X121L858R and Del-19121L861Q). 20, 34 However, our study showed that a de novo drug-resistant mutation (eg, 20T790M or 20 insertion) in conjunction with 21L858R had the highest frequency of occurrence.
The ORR and PFS were the best for patients with double classic mutations (group A), and they were similar to those in a previous study and our literature review 20 ( Table 3 ). To the best of our knowledge, a median PFS of 18.2 months was the best PFS in comparison with other results. In addition, our investigation was also supported by preclinical data, which showed that autophosphorylation of the intracellular kinase domain was inhibited more in cell lines with double classic mutations than single EGFR mutations when they were exposed to the same TKI concentrations 21 ; this suggests that first-generation TKIs may be more effective for this patient population. It is well established that single classic mutations (Del-19 and 21L858R) are the best predictors for firstgeneration TKIs. However, the response pattern and clinical outcomes have remained unknown when a second atypical mutation is introduced. In our study, patients harboring complex mutations with a classic mutation pattern (Del-19/21L858R1atypical mutation; group B) derived clinical outcomes similar to those of patients who had only 1 classic mutation (Del-19/21L858R). This result has been confirmed by other reports. Wu et al 15 reported that no difference was observed in the ORR (83% vs 73%) or PFS (12.7 vs 8.1 months) between patients with complex mutations with a classic pattern and those with single sensitive mutations. It is, therefore, reasonable to conclude that the introduction of a second atypical mutation to Del-19/21L858R does not obviously alter the sensitivity to TKIs.
Previous studies, together with our published results, suggested that single atypical mutations, mainly 18G719X, 20S768I, and 21L861Q, are slightly sensitive to TKI treatments. 35, 36 However, the response pattern for patients with double atypical mutations was inconsistent. Reported ORRs varied and ranged from 29% to 87.5%. 12, 15, 16 Moreover, the PFS was also controversial, and the best survival time was reported to be 12.0 months. 12 A discrepancy with previous studies was also observed in our study, and this suggested that the coexistence of atypical mutations was similar to single classic mutations in terms of the ORR and PFS. Small sample sizes partially caused the controversial results. In addition, the response to TKIs depends on the interaction between the TKIs and the intracellular kinase domain, which is mainly affected by molecular conformations. Currently, almost 200 EGFR mutation types have been identified, and the great heterogeneity in complex atypical mutations may also be responsible for the contradictory results. 37 We noted the poorest ORR and PFS for patients with a primary 20T790M or 20 insertion (group D), even with the presence of sensitive mutations (Del-19/ 21L858R/21L861Q), and this might reflect de novo drug resistance. This result was consistent with earlier reports, which showed that patients who had a concomitant classic mutation and a T790M point mutation were resistant to first-generation TKIs. 38 In addition to first-generation TKIs, the effect of a second-generation TKI (afatinib) was also analyzed in these patients; this resulted in an ORR and PFS of only 14.3% and 8.9%, respectively. 39 On the basis of these results together with previous results, it seems that first-or second-generation TKIs may be ineffective on the whole. For these patients, third-generation TKIs (eg, AZD9291) or chemotherapy may be a better choice. 40 Our study is limited by its retrospective design. Moreover, 2 different detection methods were used during the study period, and this might have affected the ORR, disease control rate, and PFS. However, the 2 methods had similar sensitivities, and the majority of the patients (81.8% [13,772 of 16,840] ) were analyzed by the ARMS method; thus, the effect might be slight. Moreover, although the case number in this study was larger in comparison with previous studies, the great heterogeneity of atypical mutations enabled us to perform further subgroup analyses in groups B and C, so we anticipate more studies and reports in this field.
In conclusion, we have reported on a large case number of patients with non-small cell lung cancer and complex EGFR mutations and their responses to TKIs. Complex EGFR mutations accounted for 3.2% of the entire EGFR mutation spectrum, and they included a variety of mutation types. Patients with double classic mutations had the best ORR and PFS in comparison with patients with other mutation types, and they may have benefitted more from TKI treatments. In addition, those who had complex mutations with a classic pattern and those with double atypical mutations derived similar PFS in comparison with patients who had single classic mutation. Moreover, the introduction of a sensitive mutation to a T790M mutation did not increase the effectiveness of TKIs treatments. Overall, this study has increased our knowledge of the entire EGFR mutation spectrum and should assist clinicians in developing more tailored therapies.
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